This is our FY23 November letter. It's our second appeal of the year that is sent to our Cancer Discovery Fund donor and prospects. It includes audiences of: 1XLY, LY, SY, LAP, FUT and for the first time CCT (cancer clinical trials grateful patients/non-donors). Because we added the CCT segment, our HH count doubled. And so did, our donors and dollars at 301 gifts at $33,450. Response rate decreased by 6% (1.29%) from the previous year. This was the best year for this appeal as we saw lower number in FY24 possibly due to our variable language change. The message was optimistic and research-based.
Submitted for Writing Workshop